131 related articles for article (PubMed ID: 10487829)
1. Study of p53 in elderly patients with myelodysplastic syndromes by immunohistochemistry and DNA analysis.
Kikukawa M; Aoki N; Sakamoto Y; Mori M
Am J Pathol; 1999 Sep; 155(3):717-21. PubMed ID: 10487829
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
3. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia.
Iwasaki T; Murakami M; Sugisaki C; Sobue S; Ohashi H; Asano H; Suzuki M; Nakamura S; Ito M; Murate T
Pathol Int; 2008 Jun; 58(6):353-60. PubMed ID: 18477214
[TBL] [Abstract][Full Text] [Related]
4. p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia.
Kitagawa M; Yoshida S; Kuwata T; Tanizawa T; Kamiyama R
Am J Pathol; 1994 Aug; 145(2):338-44. PubMed ID: 8053492
[TBL] [Abstract][Full Text] [Related]
5. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
Estey EH; Keating MJ; Dixon DO; Trujillo JM; McCredie KB; Freireich EJ
Hematol Pathol; 1987; 1(4):203-8. PubMed ID: 3504436
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-specific reduction in the expression of granulocyte--macrophage colony-stimulating factor receptor subunits in myelodysplastic syndromes.
Shikama Y; Shichishima T; Ohto H; Jubinsky PT; Maruyama Y
Br J Haematol; 2000 Dec; 111(3):863-72. PubMed ID: 11122148
[TBL] [Abstract][Full Text] [Related]
7. Internal tandem duplication of fms-like tyrosine kinase 3 is associated with poor outcome in patients with myelodysplastic syndrome.
Shih LY; Lin TL; Wang PN; Wu JH; Dunn P; Kuo MC; Huang CF
Cancer; 2004 Sep; 101(5):989-98. PubMed ID: 15329908
[TBL] [Abstract][Full Text] [Related]
8. P53 mutation in advanced stage of primary myelodysplastic syndrome.
Tang JL; Tien HF; Lin MT; Chen PJ; Chen YC
Anticancer Res; 1998; 18(5B):3757-61. PubMed ID: 9854490
[TBL] [Abstract][Full Text] [Related]
9. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis.
Lepelley P; Preudhomme C; Vanrumbeke M; Quesnel B; Cosson A; Fenaux P
Leukemia; 1994 Aug; 8(8):1342-9. PubMed ID: 8057671
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan.
Toyama K; Ohyashiki K; Yoshida Y; Abe T; Asano S; Hirai H; Hirashima K; Hotta T; Kuramoto A; Kuriya S
Leukemia; 1993 Apr; 7(4):499-508. PubMed ID: 8464227
[TBL] [Abstract][Full Text] [Related]
11. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
[TBL] [Abstract][Full Text] [Related]
12. The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML.
Kaeferstein A; Krug U; Tiesmeier J; Aivado M; Faulhaber M; Stadler M; Krauter J; Germing U; Hofmann WK; Koeffler HP; Ganser A; Verbeek W
Leukemia; 2003 Feb; 17(2):343-9. PubMed ID: 12592334
[TBL] [Abstract][Full Text] [Related]
13. Expression of type 1 insulin-like growth factor receptor in marrow nucleated cells in malignant hematological disorders: correlation with apoptosis.
Qi H; Xiao L; Lingyun W; Ying T; Yi-Zhi L; Shao-Xu Y; Quan P
Ann Hematol; 2006 Feb; 85(2):95-101. PubMed ID: 16328478
[TBL] [Abstract][Full Text] [Related]
14. Absence of p16 and p27 gene rearrangements and mutations in de novo myelodysplastic syndromes.
Papageorgiou SG; Pappa V; Papageorgiou E; Tsirigotis P; Kontsioti F; Panani A; Dervenoulas J; Economopoulos T
Eur J Haematol; 2005 Sep; 75(3):193-8. PubMed ID: 16104874
[TBL] [Abstract][Full Text] [Related]
15. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
16. p53 mutation in the myelodysplastic syndromes.
Adamson DJ; Dawson AA; Bennett B; King DJ; Haites NE
Br J Haematol; 1995 Jan; 89(1):61-6. PubMed ID: 7833278
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneous patterns of CEBPalpha mutation status in the progression of myelodysplastic syndrome and chronic myelomonocytic leukemia to acute myelogenous leukemia.
Shih LY; Huang CF; Lin TL; Wu JH; Wang PN; Dunn P; Kuo MC; Tang TC
Clin Cancer Res; 2005 Mar; 11(5):1821-6. PubMed ID: 15756005
[TBL] [Abstract][Full Text] [Related]
18. Mutational analysis of the KIT gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia.
Lorenzo F; Nishii K; Monma F; Kuwagata S; Usui E; Shiku H
Leuk Res; 2006 Oct; 30(10):1235-9. PubMed ID: 16533529
[TBL] [Abstract][Full Text] [Related]
19. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
20. No concomitant occurrence of the N-ras and p53 gene mutations in myelodysplastic syndromes.
Mitani K; Hangaishi A; Imamura N; Miyagawa K; Ogawa S; Kanda Y; Yazaki Y; Hirai H
Leukemia; 1997 Jun; 11(6):863-5. PubMed ID: 9177441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]